Correction to: British Journal of Cancer (2016) 115, 188–194. doi: 10.1038/bjc.2016.185; Published online 28 June 2016.
Upon publication of the above paper in the British Journal of Cancer, the authors identified several errors in their manuscript and Supplementary Material.
Table 3 contained minor rounding errors and was incorrectly formatted. The correct table has been reproduced below.
On page 5, the second sentence in the discussion section omitted a reference and contained a minor numerical error. The sentence should read:
‘Indeed, the median OS of patients in the nab-P+Gem group who received a 2L treatment was over 4 months longer than the median OS with nab-P+Gem in the ITT population (12.8 vs 8.7 months; Von Hoff et al, 2013; Goldstein et al, 2015) and over 6 months longer than the median OS with nab-P+Gem in patients who did not receive 2L therapy (12.8 vs 6.3 months).’
Supplementary Figure 1 has been replaced in the original supplementary file list, with a number of values having been changed.
The authors apologise for these oversights.
Change history
25 October 2016
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, Tortora G, Van Laethem JL, Young R, Penenberg DN, Lu B, Romano A, Von Hoff DD (2015) nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst e-pub ahead of print 31 January 2015 doi:10.1093/jnci/dju413.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: 1691–1703.
Additional information
Supplementary Information accompanies this paper on British Journal of Cancer website
The online version of the original article can be found at 10.1038/bjc.2016.185
Supplementary information
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
About this article
Cite this article
Chiorean, E., Von Hoff, D., Tabernero, J. et al. Erratum: Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer 115, e13 (2016). https://doi.org/10.1038/bjc.2016.306
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2016.306
